Effect of an Oral Shiga Toxin-Binding Agent on Diarrhea-Associated Hemolytic Uremic Syndrome in Children: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 10, 2003, Pages 1337-1344

  Trachtman, Howard ^a   Cnaan, Avital ^b   Christen, Erica ^a   Gibbs, Kathleen ^b   Zhao, Sanyi ^b   Acheson, David W K ^c   Weiss, Robert ^d   Kaskel, Frederick J ^e   Spitzer, Adrian ^e   Hirschman, Gladys H ^f  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SHIGA TOXIN; SYNSORB PK; UNCLASSIFIED DRUG; ORGANOSILICON DERIVATIVE; TRISACCHARIDE;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; CANADA; CEREBRAL BLINDNESS; CHILD; CLINICAL TRIAL; COMA; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GALLBLADDER DISEASE; GANGRENE; HEART ARRHYTHMIA; HEMOLYTIC UREMIC SYNDROME; HOSPITAL DISCHARGE; HUMAN; INFANT; INTESTINE PERFORATION; INTUSSUSCEPTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEIZURE; SIDE EFFECT; STROKE; TREATMENT OUTCOME; UNITED STATES; VOMITING; AMBULATORY CARE; CHEMISTRY; FECES; GENETICS; HOSPITALIZATION; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; DIARRHEA; DOUBLE-BLIND METHOD; FECES; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HOSPITALIZATION; HUMANS; INFANT; MALE; ORGANOSILICON COMPOUNDS; SHIGA TOXINS; TRISACCHARIDES;

EID: 0041411080     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.10.1337     Document Type: Article

References (28)

1. Trachtman H, Christen C. Hemolytic uremic syndrome. Curr Opin Pediatr. 1999;11:162-168.
2. Kaplan BA, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998;9:1126-1133.
3. Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr. 1994;125:511-518.
4. Andreoli SP, Trachtman H, Acheson DWK, et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol. 2002;17:293-298.
5. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:823-839.
6. Armstrong GD, Fodor E, Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis. 1991;164:1160-1167.
7. Armstrong GD, Rowe PC, Goodyer P, et al. A phase I study of chemically synthesized Verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to Chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis. 1995;171:1042-1045.
8. Lopez EL, Devoto S, Fayad A, et al. Association between the severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome. J Pediatr. 1992;120:210-215.
9. Meyers KEC, Kaplan BS. Hemolytic uremic syndrome. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th ed. Baltimore, Md: Williams & Wilkins; 1998:811-822.
10. Schulman SL, Kaplan BS. Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. Pediatr Nephrol. 1996;10:671-674.
11. Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of hemolytic uremic syndrome. N Engl J Med. 1992;327:755-759.
12. Dalton RN, Haycock GB. Laboratory investigation. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th ed. Baltimore, Md: Williams & Wilkins; 1998:354.
13. Hull AE, Acheson DWK, Echeveria P, et al. Mitomycin C immunoblot colony assay for the detection of Shiga-like toxin producing E coli in fecal samples. J Clin Microbiol. 1993;31:1167-1172.
14. Rowe PC, Orrbine E, Wells GA, McLaine PN. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1899. J Pediatr. 1991;119:218-224.
15. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998;352:1207-1212.
16. Banatvala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study. J Infect Dis. 2001;183:1063-1070.
17. Karch H, Bielaszewska M, Bitzan M, Schmidt H. Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. Diagn Microbiol Infect Dis. 1999;34:229-243.
18. Takeda T, Yoshino K, Adachi E, et al. In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb PK) as a specific absorbing agent of Shiga toxin 1 and 2. Microbiol Immunol. 1999;43:331-337.
19. Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis. 2002;186:57-63.
20. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature. 2000;403:669-672.
21. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dystentery in humans. Nat Med. 2000;6:265-270.
22. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin producing Escherichia coli O157:H7. Proc Natl Acad Sci U S A. 2002;99:7669-7674.
23. Te Loo DM, van Hinsbergh VW, van den Heuvel LP, Monnens LA. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol. 2001;12:800-806.
24. Yamagami S, Motoki M, Kimura T, et al. Effect of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001;184:738-742.
25. Kimura T, Co MS, Vasquez M, et al. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid Hybridomics. 2002;21:161-168.
26. Mukherjee J, Chios K, Fishwold D, et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun. 2002;70:612-619.
27. Diez-Gonzalez F, Callaway TR, Kizoulis MG, Russell JB. Grain feeding and the dissemination of acid-resistant Escherichia coli from cattle. Science. 1998;281:1666-1668.
28. Thayer DW, Boyd G. Elimination of Escherichia coli O157:H7 in meats by gamma irradiation. Appl Environ Microbiol. 1993;59:1030-1034.